It’s time for the Lightning Round. Cramer makes the call on viewer favorites.» Read More
Dec 3- Patients who are being treated for a leading cause of blindness among the elderly might be able to scale back on eye injections if trials confirm the potential of an eye drop being developed by a small New York- based company.
Nov 5- Regeneron Pharmaceuticals Inc on Tuesday reported quarterly profit that beat analyst expectations and again raised its forecast for its high-flying Eylea eye drug, sending its shares up by more than 7 percent.
Nov 5- Regeneron Pharmaceuticals Inc on Tuesday reported quarterly earnings that beat analyst expectations and also raised its forecast for its Eylea eye drug again, although it said growth of that key treatment slowed again during the past three months.
It looks like next week could be a big week in the market. Are you ready?
Oct 22- Amgen Inc, which this month closed a nearly $10 billion acquisition of cancer drug maker Onyx Pharmaceuticals, reported higher-than-expected, third-quarter profit as results were helped by a large U.S. government order for one of its white blood cell boosters.
Oct 21- Regeneron Pharmaceuticals Inc said its drug Eylea improved vision in a late-stage trial far better than standard laser treatment among patients with a common form of vision loss caused by blood clots in secondary veins of the retina.
Has Washington distracted you from these money making developments?
Take a look at some of Wednesday's midday movers:
NEW YORK/ PARIS, Oct 16- A new type of cholesterol drug from Regeneron Pharmaceuticals Inc and Sanofi SA, when used by itself, cut levels of "bad" LDL cholesterol almost in half in the first of a dozen late-stage trials of the medicine.
Biotech stocks are some of Nasdaq's best performing this year. Joel Sendek, Stifel Nicolaus, looks at names leading the biotech boom.
Sure the shutdown could become frightening. But Cramer doesn’t want it to scare you out of stocks entirely.
Cramer says these 10 stocks are still 'buys' even if the DC debt debacle gets really nasty.
**APPLE INC, $462.35, up 1.5 pct. The fingerprint reader on Apple's top-end iPhone 5 S received an early thumbs up for ease of use from two influential reviewers, helping dispel concerns about the scanning technology which has been notoriously unreliable in other cellphones. BLACKBERRY, $10.45, down 1 pct.
Since Lehman filed for bankruptcy five years ago, a screen of the S&P 500 reveals that about 20 percent of the index components remain in the red.
**COOPER TIRE AND RUBBER CO, Friday close $33.22, down 4 pct premarket. A U.S arbitrator said Cooper Tire and Rubber Co cannot sell two of its factories in the country to India's Apollo Tyres until a collective bargaining agreement is reached between Apollo and members of the plants' union. **SPLUNK INC, Friday close $59.54, up 4 pct premarket.
Jefferies on Monday also upgraded Huntsman to "buy", citing gains in 2014-2015 from its propylene oxide-making joint venture with China's refiner Sinopec Corp, which is expected to be completed by the end of next year and its presence in Europe, among other things. **BOEING CO, Friday close $111.33.
PARIS/ LONDON, Sept 13- Repurchasing L'Oreal's 9 percent stake in Sanofi might make sense for the French drugmaker if the $12 billion holding is put up for sale, Sanofi's chief executive said on Friday.
**LAKELAND INDUSTRIES INC, $5.70, up 37 pct. The safety gear retailer's second-quarter earnings more than doubled to $4.2 million, or 74 cents per share, helped by higher revenue from the United States and China and lower operating expenses.
There are a handful of stocks out there that the market loves and should take even higher by the end of the year, CNBC's Jim Cramer said Thursday.
CNBC’s Analytics team looked at the stocks that have average consensus estimates farthest above their current stock prices. Here's what they found.